iRhythm Holdings, Inc.

IRTC
About the company

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.

Country: United StatesPrice: $91.91Market Cap: $3.1B

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

3 / 13

NEUTRAL / FAIL

Median fair value

$28.98

-68.5% vs price

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #1990 (Top 64.3%)NEUTRALFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/A-370.4%N/AN/AN/A-139.2%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-19

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Profitability0% pass✓ 6✗ 29▾

      No clean pass — all 16 investors flag at least one profitability criterion

      Positive EPS (10 years)0/13 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/13 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-59.4%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-7.7% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-44.6M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-21.8%
      ✗Lynch> 15%
      EBIT / Enterprise Value-2.0%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-2.0%, ROC=-12.3%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-4.37%
      ✗PiotroskiROA > 0
      ROA Change YoY-12.16% -> -4.37% (delta: +7.80%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=7.93%, ROA=-4.37%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY68.9% -> 70.6%
      ✓PiotroskiImproved YoY
      Pre-Tax Income / Revenue-4.4%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-21.8%
      ✗Dreman> 12%
      Margin of SafetyP/B=19.4x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-70.8% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/12 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-5.7%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-21.8%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-25.4% (2023) -> -7.7% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 67.3% -> 70.6%, operating margin -25.4% -> -7.7%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-1.27%; #3450/6340 (top 54.4%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+56.54%; #533/3702 (top 14.4%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity-21.79%; #3731/5226 (top 71.4%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0901; #3346/5884 (top 56.9%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio19.4x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-2.0%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-2.0%, ROC=-12.3%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)36.6x
      ✗Dreman< 8x
      Price / Book Value per Share19.4x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-2.4%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=1.1%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=19.4x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share85.7x
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($91.91)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-1.27%; #3450/6340 (top 54.4%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.0581; #4963/6449 (top 77.0%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share19.48x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change-59.5%
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.2800; #3413/5247 (top 65.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization+0.24%; #2493/4519 (top 55.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-20.24%; #3981/6202 (top 64.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 3✗ 10▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 18.7% vs Rev: 21.6%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-12.05 (2014) -> $-1.39 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/12 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth20.1%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency2/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 67.3% -> 70.6%, operating margin -25.4% -> -7.7%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR23.0%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts0% pass✗ 14▾

      Split decision: 13 FAIL · 3 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #1990•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (2/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Valuation models0% pass✗ 2▾

      IRTC overvalued: all 2 models price fair value below $91.91 (median $28.98)

      Munger fair value$19.54
      ✗Munger-370.4% margin vs $91.91
      Ackman fair value$38.42
      ✗Ackman-139.2% margin vs $91.91
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag IRTC's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities3.57
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-5.8x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Cash Flow20% pass✓ 3✗ 9▾

      8 of 10 flag IRTC's cash flow — Buffett, Lynch, Dreman +5 more

      Free Cash Flow Proxy$-44.6M
      ✗BuffettPositive and growing
      FCF Positive and Growing$7.4M
      ✗LynchPositive and growing
      Operating Cash Flow$80.9M
      ✓PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=7.93%, ROA=-4.37%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)36.6x
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=1.1%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive1/12 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap0.2%
      ✗Ackman>= 4%
      Price / FCF per Share85.7x
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency2/12 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$7.4M
      ✓Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization+0.24%; #2493/4519 (top 55.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag IRTC's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio3.57
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-36.1%
      ✗Buffett> 10%
      ROIC - WACC-46.1%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-12.3%
      ✗Greenblatt> 25%
      Current Ratio Change YoY5.82 -> 4.63
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.64x -> 0.73x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities3.57
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-40.4%; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/3 years above 12% (latest -40.4%)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Mid Cap($3.1B)
    Revenue: $747.1M+26.2% YoY
    Net Income: $44.6M+60.7% YoY

    Financial Snapshot

    Operating Margin-7.7%
    Return on Equity-29.2%
    Debt / Equity--
    Current Ratio4.63
    EPS (Diluted)$-1.39
    Buybacks (1y)$0
    Buybacks (2y)$25.0M
    Shares Retired−2.9% / −4.0% 2y

    Shareholder Return

    Fiscal 2025

    Issued 2.9% of shares last year, 4.0% issued over two.

    Buybacks
    $0
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, buybacks.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-02-19
    FY 2024
    Sources
    • 10-K · 2025-02-20
    FY 2023
    Sources
    • 10-K · 2024-02-22
    FY 2022
    Sources
    • 10-K · 2023-02-23
    FY 2021
    Sources
    • 10-K · 2022-02-28
    Market Cap$3.1Bcurrent------$5.0Best.$3.4Best.$3.7Best.$3.0Best.$3.7Best.
    Revenue$854.0M↑22%$221.6M↑15%$224.2M↑20%$199.4M↑26%$747.1M↑26%$591.8M↑20%$492.7M↑20%$410.9M↑27%$322.8M
    Operating Income-$49.0M↑23%-$32.6M↓286%-$2.5M↑86%-$16.2M↑50%-$57.4M↑50%-$115.5M↑8%-$125.2M↓10%-$113.8M↓14%-$99.9M
    Net Income-$38.6M↑25%-$29.9M↓473%-$381.0K↑97%-$13.9M↑55%-$44.6M↑61%-$113.3M↑8%-$123.4M↓6%-$116.2M↓15%-$101.4M
    EPS (Diluted)--$-0.90↓463%$-0.01↑98%$-0.43↑56%$-1.39↑62%$-3.63↑10%$-4.04↓4%$-3.88↓12%$-3.46
    Gross Margin72.3%↑3%74.2%↑4%72.8%↑2%70.9%↑3%70.6%↑2%68.9%↑2%67.3%↓2%68.5%↑4%66.2%
    Operating Margin-5.7%↑37%-14.7%↓236%-1.1%↑89%-8.1%↑60%-7.7%↑61%-19.5%↑23%-25.4%↑8%-27.7%↑11%-31.0%
    ROE-21.8%↑48%———-29.2%↑77%-124.6%↓112%-58.7%↓21%-48.4%↓34%-36.3%
    Total Debt------------$35.0M$34.9M↑64%$21.4M
    Shareholders' Equity$177.1M↑45%$177.1M↑45%$186.0M↑79%$161.2M↑86%$152.7M↑68%$90.9M↓57%$210.1M↓12%$239.8M↓14%$279.5M
    Current Ratio3.57↓23%3.57↓23%3.85↓23%5.17↓10%4.63↓21%5.82↑171%2.15↓34%3.24↓7%3.48
    Debt / Equity——————0.17↑14%0.15↑91%0.08
    Operating Cash Flow$55.6M↓25%$4.4M↓87%$51.1M↑85%-$26.2M↓232%$80.9M↑2285%$3.4M↑107%-$50.1M↓118%-$23.0M↑39%-$37.8M
    Free Cash Flow$7.4M↓77%-$11.5M↓158%$37.5M↑117%-$33.1M↓91%$34.5M↑213%-$30.6M↑66%-$90.5M↓71%-$52.8M↑20%-$65.8M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    IRTC vs Peers — Financial Grading

    Revenue$747.1MMedian
    Net Income$44.6MBottom 25%
    ROE-29.2%Bottom 25%
    D/E—
    Op. Margin-7.7%Bottom 25%
    Curr. Ratio4.63Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11